Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma - Join Clinical Trial NCTNCT04512716
How to Join This Clinical Trial - NCTNCT04512716
Learn how to participate in this EARLY_PHASE1 trial studying an investigational therapy for B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
- Treatment Being Tested
- Investigational treatment
- Study Phase
- EARLY_PHASE1 - Early safety study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT04512716 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 7 locations. Find a study site near you:
Clinical Research Site
Basking Ridge, New Jersey 07920 - United States
Status: RECRUITING
Clinical Research Site
Middletown, New Jersey 07748 - United States
Status: RECRUITING
Clinical Research Site
Montvale, New Jersey 07645 - United States
Status: RECRUITING
Clinical Research Site
Commack, New York 11725 - United States
Status: RECRUITING
Clinical Research Site
Harrison, New York 10604 - United States
Status: RECRUITING
Clinical Research Site
New York, New York 10065 - United States
Status: RECRUITING
Clinical Research Site
Rockville Centre, New York 11553 - United States
Status: RECRUITING
How to Enroll in This Study
To learn more about participating in this EARLY_PHASE1 clinical trial for B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships